programas cribado cancer
INICIO / CÁNCER DE MAMA / ACTUALIZACIÓN BIBLIOGRÁFICA / NOTA BIBLIOGRáFICA CRIBADO C MAMA 2013-03

Nota bibliográfica cribado c mama 2013-03

Correspondencia artículo:  Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review.  Lancet, 380 (2012), pp. 1778–1786:

Autier P, Boniol M, Boyle P. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):800. DOI:10.1016/S0140-6736(13)60620-0.

Bird SM. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):802-803. DOI:10.1016/S0140-6736(13)60625-X.

Donzelli A. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):799-800. DOI:10.1016/S0140-6736(13)60619-4.

Duffy SW. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):802. DOI:10.1016/S0140-6736(13)60624-8.

Gøtzsche PC, Jørgensen KJ. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):799. DOI:10.1016/S0140-6736(13)60618-2.

Hanley JA, Liu Z, McGregor M. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):800. DOI:10.1016/S0140-6736(13)60621-2.

Paci E, Broeders M, Hofvind S, Duffy SW. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):800-801. DOI:10.1016/S0140-6736(13)60622-4.

Zahl P. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):801-802. DOI:10.1016/S0140-6736(13)60623-6.

Mühlhauser I. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):803. DOI:10.1016/S0140-6736(13)60626-1.

Jatoi I. The benefits and harms of breast cancer screening. The Lancet 2013 3/9–15;381(9869):803. DOI:10.1016/S0140-6736(13)60627-3.

The benefits and harms of breast cancer screening – Authors' reply. (carta). The Lancet 2013 3/9–15;381(9869):803-804. DOI:10.1016/S0140-6736(13)60628-5

 
 
Duffy S, Mackay J, Thomas S, Anderson E, Chen T, Ellis I, et al. Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study. Health Technol Assess 2013 Mar;17(11):1-95. DOI:10.3310/hta17110; 10.3310/hta17110. PMID:23489892.

CONCLUSIONS: Annual mammography in women aged 40-49 years with a significant family history of breast or ovarian cancer is both clinically effective in reducing breast cancer mortality and cost-effective. There is a need to further standardise familial risk assessment, to research the impact of digital mammography and to clarify the role of breast density in this population.
balidea
web desarrollada y mantenida por :